Cytotoxic T cell

A cytotoxic T cell (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cells or killer T cell) is a T lymphocyte (a type of white blood cell) that kills cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways.

Most cytotoxic T cells express T-cell receptors (TCRs) that can recognize a specific antigen. An antigen is a molecule capable of stimulating an immune response, and is often produced by cancer cells or viruses. Antigens inside a cell are bound to class I MHC molecules, and brought to the surface of the cell by the class I MHC molecule, where they can be recognized by the T cell. If the TCR is specific for that antigen, it binds to the complex of the class I MHC molecule and the antigen, and the T cell destroys the cell.

In order for the TCR to bind to the class I MHC molecule, the former must be accompanied by a glycoprotein called CD8, which binds to the constant portion of the class I MHC molecule. Therefore, these T cells are called CD8+ T cells.

Podcasts:

PLAYLIST TIME:

Latest News for: cd8 t cells

Chinese team develops breakthrough vaccine molecule

China Daily 27 Mar 2025
It also boosts the cellular immune response of CD8+ T cells, which play a crucial role in protecting against viral infections and eliminating tumors, Wang said.

Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development

Pharmiweb 26 Mar 2025
Immunogenicity analysis showed neoantigen-specific T cell responses in 100% of evaluable participants (N=37). NOUS-209 induced robust, polyfunctional and durable CD8 and CD4 T cell responses against multiple frameshift peptide (FSP) neoantigens.

B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 24 Mar 2025
Stay ahead with the most recent pipeline outlook for B-Cell Lymphoma ... Its primary goal is to enhance the immune system's capacity to combat cancer by boosting the proliferation and survival of natural killer (NK) cells and memory CD8+ T cells.

Releasing the Brakes: The Role of Immune Checkpoint Inhibitors in Cancer Therapy

The Scientist 13 Mar 2025
For CD4+ and CD8+ T cells to function properly, they require two activation signals.5 First, they must recognize an antigen presented on the major histocompatibility complex (MHC) of ...

ReiThera to Unveil ReiCell-AAV Platform for High-Efficiency Gene Therapy AAV Production, Adding to MVA and GRAd Vector Capabilities

Pharmiweb 12 Mar 2025
... leverages a proprietary gorilla adenovirus vector with low seroprevalence in humans, making it an ideal candidate for strong and sustained immune responses in particular for CD8 T-Cell based immunity.
  • 1
×